Christine Goddard, Ph.D., focuses her practice on life sciences patent procurement, strategic portfolio management, and general patent counseling, particularly in the area of pharmaceuticals. She is sought out for her expertise and experience by both small and large pharmaceutical companies to develop strong patent positions with respect to existing and future drug products. Dr. Goddard regularly advises clients with respect to identification of patentable inventions, patentability searches, patent preparation, patent prosecution strategies, global filing strategies, state of the art and patent landscape searches, freedom to operate opinions, due diligence, licensing, contracts, and assignment of patent rights.
Dr. Goddard’s prior experience includes work in-house at Bristol-Myers Squibb as well as at two law firms in the Philadelphia area. In the pharmaceutical and biotechnology realm, she has particular experience in medicinal chemistry including synthesis and characterization of molecules, pharmaceutical formulations, isomers, isotopes, metabolites, salt forms, and crystalline forms (e.g, polymorphs). She has also advised in the areas of diagnostic and therapeutic proteins, DNA libraries, directed evolution techniques, chemical indicators, genes, proteins, antibodies, optical fibers, optical devices including OLEDs, solid catalysts, petroleum processing, ink formulations, and more.
Prior to her law career, Dr. Goddard gained extensive experience in the synthesis and characterization of organic compounds and transition metal complexes while working on projects related to the structural mimicry of metalloenzyme active sites at Harvard University. In particular, she regularly characterized compounds using X-ray crystallography, electrochemistry, NMR, IR, and mass spectrometry and gained experience in air-sensitive synthetic techniques. Her experience also includes analytical work at the Woods Hole Oceanographic Institute as a summer fellow where she helped develop methods for measuring nitrates in seawater. She has also worked in the area of biochemistry related to the isolation, purification, and structural characterization of membrane-bound photosynthetic proteins.
Chapter “Polymorphs” in course materials for Patent Resources Group course entitled Pharma & Biotech Strategies for Patent Prosecution, Hatch-Waxman, Litigation and Licensing.
“Case Study: Falana v. Kent State,” Law360, May 7, 2012.
“1st-To-File System Isn’t New To Drug Companies,” Law360, March 5, 2013.
Janis Fraser and Christine Goddard, “Bulletproofing Pharma Patents,” Life Sciences IP Review Newsletter, December 14, 2014.
Named one of the 2018 “Women Worth Watching” by Profiles in Diversity Journal.
Named Massachusetts Rising Star by Super Lawyers, 2016-2020.
- IP Licensing, Transactions, and Agreements
- Opinions and Strategic Counseling
- Patent Portfolio Management
- Patent Prosecution
J.D. cum laude, Suffolk University Law School (2010)
Ph.D., Bio-inorganic Chemistry, Harvard University (1999)
S.B., Chemistry, Massachusetts Institute of Technology (1993)
- U.S. Patent and Trademark Office 2000
- Massachusetts 2010
Member, American Chemical Society
Member, American Bar Association
Member, Women in Bio, Boston Chapter
Member, Boston Patent Law Association
January 29th, 2020
Boston Seminar Series: 2019 Year in Review
July 26, 2018
Fish & Richardson Attorneys Named 2018 “Women Worth Watching” by Profiles in Diversity Journal
April 4th, 2018 | 5:30 pm EDT
2018 Carothers Award Symposia
December 30, 2014
Bulletproofing Pharma Patents
May 21st, 2014
The USPTO Extends its Ability to Limit Examination of Markush Claims
March 5, 2013
1st-To-File System Isn't New To Drug Companies